5-(3-methoxyphenyl)-3-(methylsulfonyl)-1,2,4-triazine | 1320356-46-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-(3-methoxyphenyl)-3-(methylsulfonyl)-1,2,4-triazine
• 英文别名: 3-(Methylsulfonyl)-5-(3-methoxyphenyl)-1,2,4-triazine；5-(3-methoxyphenyl)-3-methylsulfonyl-1,2,4-triazine
• CAS: 1320356-46-4
• 化学式: C₁₁H₁₁N₃O₃S
• 分子量: 265.293
• InChiKey: XGFVZJSJGZJIRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  90.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-(3-methoxyphenyl)-3-(methylsulfonyl)-1,2,4-triazine 在 甲醇 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 氯苯 、 乙腈 为溶剂， 反应 5.0h， 生成 2-(3-methoxyphenyl)-7,8-dihydro-5H-thiopyrano[4,3-b]pyridine
  参考文献：
  名称：

  有机催化的Thia-Michael加成反应和对3-乙烯基-1,2,4-三嗪平台的顺序电子逆序Diels-Alder反应

  摘要：

  这项工作强调了将3-乙烯基-1,2,4-三嗪用作原始的thia-Michael受体和要求反电子的Diels-Alder平台，用于新的7,8-dihydro-5 H -thiopyrano [4,3- b ]吡啶。所需但相当不稳定的炔丙基硫醇亲核试剂是在相应的炔丙基硫代乙酸酯衍生物的创新性DBU催化甲醇分解事件中成功地原位生成的。

  DOI：

  10.1002/adsc.201700831
• 作为产物：
  描述：

  5-(3-methoxyphenyl)-3-(methylthio)-1,2,4-triazine 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.08h， 以58%的产率得到5-(3-methoxyphenyl)-3-(methylsulfonyl)-1,2,4-triazine
  参考文献：
  名称：

  Domino Aza-Michael-ih-Diels–Alder Reaction to Various 3-Vinyl-1,2,4-triazines: Access to Polysubstituted Tetrahydro-1,6-naphthyridines

  摘要：

  A straightforward domino aza-Michael-inverseelectron-demand-hetero-Diels Alder/retro-Diels-Alder reaction between primary and secondary propargylamine derivatives and 3-vinyl-1,2,4-triazines is developed highlighting not only the uniqueness of this dual-heterocyclic platform but also a novel and unprecedented path to polysubstituted tetrahydro-1,6-naphthyridine scaffolds.

  DOI：

  10.1021/acs.orglett.7b02132

文献信息

• [EN] 1,2,4-TRIAZINE-4-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZINE-4-AMINE
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2011095625A1

  公开（公告）日：2011-08-11

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

  根据该发明提供了一种A1式化合物，可能对通过抑制A1-A2b或特别是A2a受体而得到改善的疾病或紊乱治疗有用，其中A1式化合物具有以下结构，其中，A代表Cy1或HetA；Cy1代表一个由一个、两个或三个环组成的5-至14-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy1基团可选择地被一个或多个R4a取代基所取代；HetA代表一个由一个、两个或三个环组成的5-至14-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个、两个或三个环，且该HetA基团可选择地被一个或多个R4b取代基所取代；B代表Cy2或HetB；Cy2代表一个由一个或两个环组成的3-至10-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy2基团可选择地被一个或多个R4c取代基所取代；HetB代表一个由一个或两个环组成的3-至10-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个或两个环，且该HetB基团可选择地被一个或多个R4d取代基所取代。
• 1,2,4-TRIAZINE-4-AMINE DERIVATIVES
  申请人：Congreve Miles Stuart

  公开号：US20130029963A1

  公开（公告）日：2013-01-31

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.

  根据本发明提供了一种A1式化合物，该化合物可能有用于治疗通过抑制A1-A2bor，特别是A2a受体而改善的疾病或疾病状态，其中A1式化合物具有以下结构，其中A代表Cy1或HetA；Cy1代表一个5到14个成员的芳香族、完全饱和或部分不饱和的碳环状环系，包括一个、两个或三个环，该Cy1基团可以被一个或多个R4a取代；HetA代表一个5到14个成员的杂环基团，可能是芳香族、完全饱和或部分不饱和的，并且其中包含一个或多个从O、S和N中选择的杂原子，该杂环基团可以包括一个、两个或三个环，该HetA基团可以被一个或多个R4b取代；B代表Cy2或HetB；Cy2代表一个3到10个成员的芳香族、完全饱和或部分不饱和的碳环状环系，包括一个或两个环，该Cy2基团可以被一个或多个R4c取代；HetB代表一个3到10个成员的杂环基团，可能是芳香族、完全饱和或部分不饱和的，并且其中包含一个或多个从O、S和N中选择的杂原子，该杂环基团可以包括一个或两个环，该HetB基团可以被一个或多个R4d取代。
• 1,2,4-triazine-4-amine derivatives
  申请人：Congreve Miles Stuart

  公开号：US08809525B2

  公开（公告）日：2014-08-19

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

  根据该发明提供了一个A1式化合物，可能在治疗通过抑制A1-A2b或特别是A2a受体改善的疾病或疾病中有用，其中A1式化合物具有以下结构，其中，A代表Cy1或HetA；Cy1代表一个5-至14-成员的芳香，完全饱和或部分不饱和的碳环状系统，包括一个，两个或三个环，该Cy1基团可以被一个或多个R4a取代；HetA代表一个5-至14-成员的杂环基团，可以是芳香的，完全饱和或部分不饱和的，并且其中包含一个或多个从O，S和N中选择的杂原子，该杂环基团可以包括一个，两个或三个环，该HetA基团可以被一个或多个R4b取代；B代表Cy2或HetB；Cy2代表一个3-至10-成员的芳香，完全饱和或部分不饱和的碳环状系统，包括一个或两个环，该Cy2基团可以被一个或多个R4c取代；HetB代表一个3-至10-成员的杂环基团，可以是芳香的，完全饱和或部分不饱和的，并且其中包含一个或多个从O，S和N中选择的杂原子，该杂环基团可以包括一个或两个环，该HetB基团可以被一个或多个R4d取代。
• Domino Transformations of 3‐Fluoro‐1,2,4‐Triazine Derivatives towards Spirocyclic and Fused Pyridines
  作者：Anthony Lapray、Thomas Martzel、Marie‐Aude Hiebel、Sylvain Oudeyer、Franck Suzenet、Jean‐François Brière

  DOI：10.1002/adsc.202301307

  日期：2024.1.30

  intramolecular ihDA/rDA reaction of the alkyne tether gave a five-membered ring formation benefited from a Thorpe-Ingold effect. Accordingly, the cycloaddition occurred at a rather low temperature (<70 °C), in contrast to the 150–200 °C usually required in other instances.5 Unfortunately, the scope of this original C−C bond construction and stepwise strategy is rather limited, and led to yields from low to moderate

  螺吲哚是多种生物活性和天然存在的化合物的核心结构。1在该领域，方案 1A ( I , Y=CR)中描述的羟吲哚衍生的四环结构引发了各种研究，旨在详细说明该家族中的生物活性产品，或开发允许构建各种类似物的原始方法。2, 3尽管吡啶衍生物被认为是药物化学中的特殊结构，但4这种氮杂芳烃在四环化合物（例如I (Y=N)）中却出人意料地不存在，这可能是由于缺乏合适的合成策略。 方案一 在图查看器中打开微软幻灯片软件 走向融合的非芳族/杂芳族自行车：背景和新计划​​。 多米诺反电子需求杂-Diels-Alder/逆-Diels-Alder ( ih DA/ r DA) 反应发生在1,2,4-三嗪（2-氮杂二烯）和亲二烯体之间-建立有效的环加成策略来构建吡啶衍生物（方案1B）。5大量工作致力于通过双功能异亲核试剂（Nu(Het)-H、Nu=O、 3-甲基磺酰基-1,2,4-三嗪在 C3 处发生 S N Ar
• US8809525B2
  申请人：——

  公开号：US8809525B2

  公开（公告）日：2014-08-19